Updated 08:09 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,859.70 -0.68% CL 88.67 +0.12% BTC 64,634.95 -1.03%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,860 −0.68% BTC $64,635 −1.03% VIX 19.30 +3.21% latest tape · as of 08:09 UTC
The Screen · Communication Services · Telecom Services

Anterix Inc. logoAnterix Inc.

ATEX · Nasdaq · USD · Market cap $1.3B

Anterix Inc.

FAIL · Does not pass the screen
80.14 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price80.14 USD at the 13 Nov 2026 close
  • Our value readFair vs our fair value, as of 13 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.33)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $77.40 to $95.63, base estimate $83.16 (screen dated 2026-11-13).

Current read
Markup ?
Fair · screened 2026-11-13
  • Trend Markup
  • Insiders insiders sold, $400,607, latest filing 2026-10-09
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.33, read 2026-11-15
  • Ethical does not pass the values gate
Price80.14 USD
Fair value83.16
Ethical score70.0/100
Value readFairas of 13 Nov 2026
Our investment reviews on this name
2026-11-07Read Distribution74.36+7.8% to today Markup gives way to Distribution after a 9% rise in 1 days
2026-11-06Read Markup68.52+17.0% to today ✓Distribution gives way to Markup after a 12% slide in 1 days
2026-11-05Read Distribution77.76+3.1% to today Markup gives way to Distribution after a 14% slide in 2 days
2026-11-03Read Markup90.67-11.6% to today Distribution gives way to Markup after a 24% rise in 7 days

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Anterix Inc. holds its Markup at $80.14. The statistical read favours the sellers, held for 14 days.

As held on the ledger · 2026-11-13
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 14 days
Price at the screen$80.14
Valuation19.58 trailing · 33.26 forward price to earnings
Values screenFAIL · score 70.0
Beta0.86
The Workings

Five Screens, Shown in Full

Does not pass. Revenue purity

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 0.95% Below 33% Interest-bearing debt is just 0.9% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 23.47% Below 49% Money owed to the company is 23.5% of assets, under the 49% limit. Pass
Revenue purity 25.12% Below 5% 25.1% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Anterix clears the business-activity screen, and its debt is near-nil. Where it falls short is income purity: around 25% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ATEX's ethical verdict changes

Today ATEX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades at roughly a 4% discount to our $83.16 fair value, 38.10% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

77.40Conservative83.16Base case95.63Growth case 80.14Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 3.6% discount to the base estimate.

The Street's Range
86.00Street low 121.00Street average 130.00Street high 80.14Price

Third-party analyst targets: 3 covering, consensus Buy. The average target sits +51% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $83.16, with a range of $77.40 to $95.63, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it is worth knowing

A quality business: 933% profit margins. It trades close to our $83.16 fair value, so the easy discount is gone; you would be paying up for the quality.

The fundamentals · plain-English read
Forward P/E33.3xfairly priced for its growth rate
Trailing P/E19.6xreasonably valued
EPS, trailing3.50
EPS, forward2.06
Revenue growth+38.1%strong top-line growth
Profit margin933.0%highly profitable on every dollar of sales
Return on equity27.9%an exceptional return on shareholder capital
FCF yield-5.31%
Debt to equity1.43a meaningful debt load worth watching
Current ratio4.85comfortably covers its short-term bills
Beta0.86steadier than the market
Short interest, float0.14%
52-week range17.58 - 113.00
Market cap$1.3B

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ATEX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-10 Distribution $80.78 +8.6% Entry 18

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 8.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-09 Distribution $74.36 +0.0% Entry 17

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-08 Distribution $74.36 +0.0% Entry 16

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 39% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-07 Distribution · changed $74.36 +8.5% Entry 15

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 8.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 39% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-06 Markup · changed $68.52 -11.9% Entry 14

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 11.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 39% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-05 Distribution · changed $77.76 -5.4% Entry 13

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 39% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-04 Markup $82.21 -9.3% Entry 12

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 39% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-03 Markup · changed $90.67 +23.9% Entry 11

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 23.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 39% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Distribution · changed $73.16 -13.4% Entry 10

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 39% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter. Since the last review it entered the Tech 100; its composite score rose.

2026-10-20 Markup $84.48 -0.1% Entry 9

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 61% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55. Insiders have been net sellers over the past quarter.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ATEX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ATEX's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · ATEX
DateInsiderTitleTypeSharesValue
2026-10-09 Marquez Elena CFO S - Sale+OE 4,981 $400,607

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $55.72 +18.8% · $1,188 +18.8%
2 months $35.89 +84.4% · $1,844 +84.4%
3 months $38.11 +73.6% · $1,736 +73.6%
6 months $22.39 +195.5% · $2,955 +195.5%
1 year $28.38 +133.2% · $2,332 +133.2%
2 years $32.17 +105.7% · $2,057 +105.7%
3 years $33.34 +98.5% · $1,985 +98.5%
5 years $50.09 +32.1% · $1,321 +32.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ATEX does next, these words stay.

Anterix Inc. · ATEX · Markup · $80.14
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.